Latest news with #AppliedDNASciences
Business Insider
3 days ago
- Business
- Business Insider
Upcoming Stock Splits This Week (June 2 to June 6)
These are the upcoming stock splits for the week of June 2 to June 6, based on TipRanks' Stock Splits Calendar. A stock split is corporate move that increases the number of outstanding shares by distributing additional shares to existing shareholders, all without affecting the company's total market value. This typically results in a lower share price, making the stock more accessible, and potentially more attractive, to retail investors. Confident Investing Starts Here: While traditional stock splits aim to broaden appeal by lowering share prices, some companies take the opposite approach. A reverse stock split consolidates shares instead of dividing them, reducing the total count while raising the price per share. The overall market value remains unchanged, but the move is often used to comply with exchange listing requirements, such as Nasdaq's minimum price rule, and prevent delisting. Strategic actions like these, whether to draw in investors or stay listed, often offer signals that savvy traders pay attention to. Let's take a look at the upcoming stock splits for the week. ARB IOT Group (ARBB) – Singapore-based ARB IOT Group provides integrated Internet of Things (IoT) solutions, including smart buildings, industrial automation, and connected agriculture systems. On May 29, the company announced a 1-for-15 reverse stock split as part of its efforts to meet Nasdaq's minimum bid price requirement. The split is set to take effect on June 2. Lyell Immunopharma (LYEL) – Lyell Immunopharma is a clinical-stage biotech company developing T-cell reprogramming therapies for solid tumors. On May 29, the company announced a 1-for-20 reverse stock split as part of its effort to stay in line with Nasdaq's listing requirements. The split takes effect on June 2. Applied DNA Sciences (APDN) – Applied DNA Sciences develops and commercializes DNA-based technologies for therapeutic manufacturing, diagnostics, and supply chain security. On May 29, the company announced a 1-for-15 reverse stock split as part of its efforts to meet Nasdaq's continued listing standards. The split is set to take effect on June 2. Mullen Automotive (MULN) – California-based Mullen Automotive, known for its electric vehicles and battery tech, announced a 1-for-100 reverse stock split on May 29 in a bid to maintain its Nasdaq listing. The split, set to take effect on June 2, is part of the company's effort to meet minimum share price requirements and stay in compliance. Ekso Bionics (EKSO) – Ekso Bionics develops wearable robotic exoskeletons to enhance mobility for people with physical limitations and for industrial use. On May 21, EKSO announced a 1-for-15 reverse stock split to restore compliance with Nasdaq's minimum price rule. The split will take effect on June 2. AGM Group Holdings (AGMH) – AGM Group provides financial technology solutions and manufactures cryptocurrency mining equipment. On May 29, the company announced a 1-for-50 reverse stock split to meet Nasdaq listing criteria. The split will be effective on June 3. ClearOne (CLRO) – ClearOne designs and sells audio-visual communications equipment including microphones, conferencing systems, and network media streaming solutions. On May 21, the company announced a 1-for-15 reverse stock split to regain Nasdaq compliance. The split will be effective on June 2, with trading on a split-adjusted basis starting June 3. Oragenics (OGEN) – Oragenics is a biotechnology company focused on developing novel antibiotics and other treatments for infectious diseases. On May 28, the company announced a 1-for-30 reverse stock split to meet NYSE American listing standards. The split will be effective on June 3.
Miami Herald
5 days ago
- Business
- Miami Herald
Applied DNA Reschedules Intra-Quarter Webcast and Investor Update Call to June 17
STONY BROOK, NY / ACCESS Newswire / May 29, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, is rescheduling its intra-quarter webcast and investor update call to June 17, 2025, from June 3, 2025, to allow for the implementation of a reverse stock split that will become effective on June 2, 2025. Prepared remarks by members of the Applied DNA management team will be followed by a live question-and-answer session with the Company's sell-side analysts and institutional investors. Webcast and Conference Call Date & Time: Tuesday, June 17 @ 4:30 p.m. Eastern Time Dial In: Domestic callers (toll-free): 844-887-9402International callers: 412-317-6798Canadian callers (toll-free): 866-605-3852Live webcast: A replay of the conference call will be available for 7 days following the conclusion of the call: Replay for domestic callers (toll-free): 877-344-7529, replay access code 3446494Replay for international callers: 412-317-0088, replay access code 3446494Replay for Canadian callers (toll-free): 855-669-9658, replay access code 3446494 An accompanying slide presentation will be embedded in the webcast (live and replay) that will also be accessible as a stand-alone document via the 'Company Presentations' page of the Applied DNA investor relations website. The webcast replay of the call will be available approximately one hour after the end of the call on the 'Company Events' page. About Applied DNA Sciences Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we operate in two business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; and (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services. Visit for more information. Follow us on X and LinkedIn. Join our mailing list. For additional information: Investor Relations: Sanjay M. Hurry, 917-733-5573, Web: SOURCE: Applied DNA Sciences, Inc.
Miami Herald
14-05-2025
- Business
- Miami Herald
Applied DNA to Announce Second Quarter Fiscal 2025 Financial Results on May 15, Schedules Intra-Quarter Investor Update Call for June 3
STONY BROOK, NY / ACCESS Newswire / May 14, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, will release its financial results for the second quarter of fiscal year 2025 (ended on March 31, 2025) after the close of the U.S. equity markets on Thursday, May 15, 2025. The Company's Form 10-Q for the period will be filed concurrently and available on the SEC Filings page of its Investor Relations website. To align with its Annual Meeting of Stockholders on May 22 and ensure a comprehensive post-meeting update, the Company will hold an intra-quarter investor update call on June 3, on which management will discuss the Company's strategic priorities. Webcast and Conference Call Date & Time: Tuesday, June 3 @ 4:30 p.m. Eastern Time Dial In: Domestic callers (toll free): 844-887-9402International callers: 412-317-6798Canadian callers (toll free): 866-605-3852Live webcast: A replay of the conference call will be available for 7 days following the conclusion of the call: Replay for domestic callers (toll free): 877-344-7529, replay access code 3446494Replay for international callers: 412-317-0088, replay access code 3446494Replay for Canadian callers (toll free): 855-669-9658, replay access code 3446494 An accompanying slide presentation will be embedded in the webcast (live and replay) that will also be accessible as a stand-alone document via the 'Company Presentations' page of the Applied DNA investor relations website. The webcast replay of the call will be available approximately one hour after the end of the call on the 'Company Events' page. About Applied DNA Sciences Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we operate in two business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; and (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services. Visit for more information. Follow us on X and LinkedIn. Join our mailing list. For additional information:Investor Relations: Sanjay M. Hurry, 917-733-5573, ### SOURCE: Applied DNA Sciences
Associated Press
14-05-2025
- Business
- Associated Press
Applied DNA to Announce Second Quarter Fiscal 2025 Financial Results on May 15, Schedules Intra-Quarter Investor Update Call for June 3
STONY BROOK, NY / ACCESS Newswire / May 14, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ('Applied DNA' or the 'Company'), a leader in polymerase chain reaction (PCR)-based technologies, will release its financial results for the second quarter of fiscal year 2025 (ended on March 31, 2025) after the close of the U.S. equity markets on Thursday, May 15, 2025. The Company's Form 10-Q for the period will be filed concurrently and available on the SEC Filings page of its Investor Relations website. To align with its Annual Meeting of Stockholders on May 22 and ensure a comprehensive post-meeting update, the Company will hold an intra-quarter investor update call on June 3, on which management will discuss the Company's strategic priorities. Webcast and Conference Call Date & Time: Tuesday, June 3 @ 4:30 p.m. Eastern Time Dial In: A replay of the conference call will be available for 7 days following the conclusion of the call: An accompanying slide presentation will be embedded in the webcast (live and replay) that will also be accessible as a stand-alone document via the ' Company Presentations ' page of the Applied DNA investor relations website. The webcast replay of the call will be available approximately one hour after the end of the call on the ' Company Events ' page. About Applied DNA Sciences Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ('DNA'). Using the polymerase chain reaction ('PCR') to enable both the production and detection of DNA, we operate in two business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNA polymerase ('RNAP') for use in the production of mRNA therapeutics; and (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services. Visit for more information. Follow us on X and LinkedIn. Join our mailing list. For additional information: Investor Relations: Sanjay M. Hurry, 917-733-5573, [email protected] Web: ### SOURCE: Applied DNA Sciences press release
Yahoo
12-02-2025
- Business
- Yahoo
Applied DNA to Report First Quarter Fiscal 2025 Financial Results After Market Close on Thursday, February 13, 2025
Investor Call and Webcast Scheduled for 4:30 P.M ET STONY BROOK, NY / / February 12, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its first quarter fiscal 2025 financial results after the market close on Thursday, February 13, 2025. The Company will host a conference call for shareholders and the investment community at 4:30 p.m. ET on that same day. Webcast and Conference Call Date & Time: Thursday, February 13 @ 4:30 p.m. ET Dial In: Domestic callers (toll free): 844-887-9402 International callers: 412-317-6798 Canadian callers (toll free): 866-605-3852 Live webcast: A replay of the conference call will be available for 7 days following the conclusion of the call: Replay for domestic callers (toll free): 877-344-7529, replay access code 7896562 Replay for international callers: 412-317-0088, replay access code 7896562 Replay for Canadian callers (toll free): 855-669-9658, replace access code 7896562 An accompanying slide presentation will be embedded in the webcast (live and replay) that can also be accessed via the 'Company Presentations' page of the Applied DNA investor relations website ( The webcast replay of the call will be available approximately one hour after the end of the call on the 'Company Events' page ( About Applied DNA Sciences Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we operate in three primary business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; and, (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services; and (iii) the manufacture and detection of DNA for industrial supply chain security services. Visit for more information. Follow us on X and LinkedIn. Join our mailing list. For additional information: Investor Relations: Sanjay M. Hurry, 917-733-5573, Web: SOURCE: Applied DNA Sciences View the original press release on ACCESS Newswire Sign in to access your portfolio
